共 50 条
- [21] Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studies JOURNAL OF CROHNS & COLITIS, 2022, 16 : I473 - I474
- [23] Characteristics of filgotinib-treated patients with Ulcerative Colitis who achieve sustained corticosteroid-free remission: Post hoc analysis of the phase 2b/3 SELECTION study JOURNAL OF CROHNS & COLITIS, 2023, 17 : 459 - 460
- [24] Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b/3 SELECTION Trial (vol 17, pg 1207, 2023) JOURNAL OF CROHNS & COLITIS, 2024, 18 (02): : 335 - 335
- [25] Safety of Filgotinib in Crohn's Disease Compared with Ulcerative Colitis: Data from the Phase 3 DIVERSITY1 and Phase 2b/3 SELECTION Studies AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S682 - S682
- [27] Efficacy and safety outcomes of long-term treatment with filgotinib 200 mg among patients with Ulcerative Colitis: An interim analysis of SELECTIONLTE JOURNAL OF CROHNS & COLITIS, 2022, 16 : I456 - I457
- [29] Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (01): : 138 - 147
- [30] Efficacy and safety outcomes of long-term treatment with filgotinib 200 mg among patients with Ulcerative Colitis: An interim analysis of SELECTIONLTE JOURNAL OF CROHNS & COLITIS, 2022, 16 : I456 - I457